Diligence memo · auto-generated · as of July 2, 2026
Selkirk Pharma, Inc.
Selkirk Pharma, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Selkirk Pharma, Inc. operates in Manufacturing, based in SPOKANE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Selkirk Pharma, Inc. has raised $82M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $35M on 2021-12-15.
Most recent recorded round closed around 2023-08-25.
Valuation (modeled)modeled
Provath models Selkirk Pharma, Inc. at approximately $153M (range $61M–$322M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.37× the median modeled value of Series B Manufacturing companies in 2022–2024 (44 peers) — value vs value, same stage and era. Within the normal band (137% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 2.9 yr ago; this sector typically re-raises about every 12 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 95% of Manufacturing peers (3257 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: Stryve Foods, Inc., JW Rutledge Distillery, LLC, Orange EV LLC, Brondell Inc., Advantest Corp.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.